U.S. Medicine

Meeting the Challenges of Hepatocellular Carcinoma in Federal Medicine


VA Continues to Improve Management of Deadly Hepatocellular Carcinoma

WASHINGTON—With the number of veterans being diagnosed with hepatocellular carcinoma continuing to rise, the VA has implemented several new initiatives to improve outcomes for patients with this aggressive cancer. The most common type of liver... View Article

Read More Print PDF


Rising Rates of Nonalcoholic Fatty Liver Disease Drive Up Hepatocellular Carcinoma Cases

HOUSTON—A new epidemic appears poised to overtake hepatitis C as the leading cause of hepatocellular carcinoma. “Nonalcoholic fatty liver disease is the next big thing in the epidemiology of liver cancer,” said Fasiha Kanwal, MD,... View Article

Read More Print PDF

HCC Risk Remains for Some, Even After Hepatitis C is Cured

HOUSTON—The VA has announced that it expects to eliminate hepatitis C in all veterans willing and able to receive treatment by May of this year. Successful treatment for HCV also dramatically reduces the risk of... View Article

Read More Print PDF


Federal Medicine Clinicians Now Have Many More Treatment Options for HCC

RICHMOND, VA—For more than a decade after the U.S. Food and Drug Administration approved sorafenib for hepatocellular cancer, treatment options for the aggressive malignancy remained static. That changed dramatically in the last 24 months as... View Article

Read More Print PDF



Print PDF

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up